Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients

Lupus

Volumn 20, Issue 12, 2011, Pages 1260-1266

  Sazliyana, S ^a   Mohd Shahrir, M S ^a,b   Kong, Ct Norella ^a   Tan, H J ^a   Hamidon, B B ^a   Azmi, M T ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b UNIVERSITI SAINS ISLAM MALAYSIA   (Malaysia)

Author keywords

carotid media intimal thickness (CIMT); cyclosporine A; lupus nephritis; traditional cardiovascular risk factors

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS;

ADULT; APHERESIS; ARTERIAL WALL THICKNESS; ARTERY MEDIA; ARTICLE; B SCAN; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIPOPROTEIN BLOOD LEVEL; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENAL CORTEX HORMONES; ADULT; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; RISK FACTORS; YOUNG ADULT;

EID: 80053631005     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311411347     Document Type: Article

References (42)

1. Azizah MR, Ainol SS, Kong NCT, Normaznah Y, Rahim MN. Demographic, clinical and immunological features of 134 Malaysian patients with SLE. Int Med J. 2001 ; 8: 45-50 (Pubitemid 32377832)
2. Boey ML, Peebles CL, Tsay G, Feng PH, Tan EM. Clinical and autoantibody correlations in Orientals with systemic lupus erythematosus. Ann Rheum Dis. 1988 ; 47: 918-923 (Pubitemid 18263863)
3. Lee SS, Li CS, Li PC. Clinical profile of Chinese patients with systemic lupus erythematosus. Lupus. 1993 ; 2: 105-109 (Pubitemid 23186214)
4. Wang F, Wang CL, Tan CT, Manivasagar M. Systemic lupus erythematosus in Malaysia: A study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups. Lupus. 1997 ; 6: 248-253 (Pubitemid 27160643)
5. Rosner S, Ginzler EM, Diamond HS, et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum. 1982 ; 25: 612-617 (Pubitemid 12078973)
6. Boumpas DT AHI, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: Emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Medicine. 1995 ; 122: 940-950
7. Cervera R, Khamashta MA, Font J. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999 ; 78: 167-175 (Pubitemid 29231143)
8. NCT K. SLE activity measures and prognosis. Malays J Dermatol. 1996 ; 9: 15-24
9. NCT K. Editorial: Systemic lupus erythematosus in Southeast Asia. J Am Med Assoc Southeast Asia. 1993 ;: 8-10
10. Fukumoto S, Tsumagari T, Kinjo M, Tanaka K. Coronary atherosclerosis in patients with systemic lupus erythematosus at autopsy. Acta Pathol Jpn. 1987 ; 37: 1-9 (Pubitemid 17018368)
11. Bhatt SP, Handa R, Gulati GS, et al. Atherosclerosis in Asian Indians with systemic lupus erythematosus. Scand J Rheumatol. 2006 ; 35: 128-132
12. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999 ; 42: 51-60 (Pubitemid 29042570)
13. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 2399-2406 (Pubitemid 37542988)
14. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992 ; 93: 513-519
15. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 ; 44: 2331-2337 (Pubitemid 32977500)
16. Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2004 ; 43: 924-929 (Pubitemid 38996970)
17. Goldberg RJ, Urowitz MB, Ibanez D, Nikpour M, Gladman DD. Risk factors for development of coronary artery disease in womenwith systemic lupus erythematosus. J Rheumatol. 2009 ; 36: 2454-2461
18. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med. 1975 ; 58: 243-264
19. Serikova S, Kozlovskaia NL, Shilov EM. [Lupus nephritis as a factor of atherosclerosis risk in patients with systemic lupus erythematosus]. Ter Arkh. 2008 ; 80: 52-58
20. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976 ; 60: 221-225
21. Karsh J, Klippel JH, Balow JE, Decker JL. Mortality in lupus nephritis. Arthritis Rheum. 1979 ; 22: 764-769 (Pubitemid 10142185)
22. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 2407-2415 (Pubitemid 37542989)
23. Hosenpud JD, Montanaro A, Hart MV, et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med. 1984 ; 77: 286-292 (Pubitemid 14098638)
24. Diagnosis and classification of diabetes mellitus. Diabetes Care. 33 (Suppl 1). S62 - S69
25. JAMA. 2001 ; 285: 2486-2497
26. The Asia Pacific perspective: Redefining Obesity and its Treatment. Hong Kong: WHO, IOTF & IASO ; 2000 :
27. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
28. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008 ; 21: 93-111 (Pubitemid 351193107)
29. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol. 1997 ; 145: 408-415 (Pubitemid 27084212)
30. Maksimowicz-Mckinnonn K, Magder LS, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. JRheumatol. 2006 ; 33: 2458-2463 (Pubitemid 46067826)
31. Ahmad Y, Shelmerdine J, Bodill H, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): The relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford). 2007 ; 46: 983-988 (Pubitemid 47062508)
32. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus. 2000 ; 9: 170-175 (Pubitemid 30199258)
33. Ong LM, Hooi LS, Lim TO. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005 ; 10: 504-510 (Pubitemid 41727277)
34. Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986 ; 314: 614-619 (Pubitemid 16132725)
35. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003 ; 62: 1071-1077 (Pubitemid 37323571)
36. Manzi S. Systemic lupus erythematosus: A model for atherogenesis?. Rheumatology (Oxford). 2000 ; 39: 353-359 (Pubitemid 30307319)
37. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol. 2000 ; 27: 2142-2145
38. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009 ; 11: R109 - R109
39. Urowitz MB, Gladman DD. Accelerated atheroma in lupus-background. Lupus. 2000 ; 9: 161-165
40. Doria A. Atherosclerosis and lupus: What we know and what we should know. J Rheumatol. 2009 ; 36: 2380-2382
41. van Leuven SI, Kastelein JJ, Allison AC, Hayden MR, Stroes ES. Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles?. Cardiovasc Res. 2006 ; 69: 341-347 (Pubitemid 43098790)
42. Romero F, Rodriguez-Iturbe B, Pons H, et al. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis. 2000 ; 152: 127-133